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ABSTRACT: Hyponatremia is the most frequent 
fluid and electrolyte disorder in hospitalized patients 
(20%), particularly in ICU, associated with an increase 
in morbility and mortality. While hypovolaemic 
hyponatremia needs to be corrected with the 
replacement of the lost extracellular fluid by isotonic 
saline, euvolaemic (SIADH) and hypervolaemic 
hyponatremia (oedematous states like decompensated 
heart failure, liver cirrhosis, i.e.) are treated by 
restriction of fluid intake, loop diuretics and 
hypertonic saline. A novel approach consists in use of 
vaptans, non-peptide arginine vasopressin (AVP) 
receptor antagonists. Vaptans cause “aquaresis”, 
which results in the correction of plasma osmolality 
and serum sodium levels, without activation of the 
renin-angiotensin-aldosterone system or changes in 
blood pressure and renal function. In this paper we 
critically reviewed the results of the available 
randomized controlled critical trials, discussing the 
effectiveness and safety of vaptans in treating 
hypervolaemic and euvolaemic hyponatremia in 
critical patients. 
 





HYPONATREMIA: DEFINITION, SYMPTOMS 
AND CLASSIFICATIONS. 
Hyponatremia, defined as a serum sodium level below 135 
mEq/l, is the most frequent electrolyte disorder and occurs 
in 3-15 % of hospitalized patients, especially in the 
departments of Intensive Care, Cardiology, Pulmonology, 
Internal Medicine, Surgery (1, 2). 
It is defined as acute or chronic if its duration is shorter or 
longer than 48 hours respectively (3). Its clinical 
manifestation depend on many factors (time of duration, 
velocity of sodium decrease, sodium levels, patients age, 
comorbidities) (3) and can give few and aspecific signs 
and symptoms (fatigue, anorexia, nausea, behavioral 
alterations) when sodium level is higher than 125 mEq/l or 
the hyponatremia is chronic or it may cause more serious 
derangements when sodium level is below 120 mEq/l or 
hyponatremia is acute (cerebral edema, encephalopathy, 
seizures, coma) (3, 4). Nevertheless, hyponatremia is a 
predictor of poor outcomes in patients with heart failure. 
Patients with heart failure and hyponatremia often have 
inappropriately elevated plasma vasopressin levels and 
significantly poorer long-term prognosis than those with 
heart failure and normal serum sodium levels. (5) 
With regard to the osmolality, except for a few cases of 
hyperosmolality hyponatremia (due to hyperglycemia or 
mannitol or other osmotic agents that cause a shift of 
water from the intracellular to the extra-cellular 
compartment), it is more frequently hypoosmolar (i.e. 
renal failure, liver cirrhosis, cardiac failure, states of 
hypovolemia, SIADH). 
The commonest classification of hyponatremia refers to 
volaemic state: a) “hypovolaemic hyponatremia” due to 
extracellular fluid loss (vomiting, diarrhea, excessive 
sweating, use of diuretics, salt wasting syndromes, adrenal 
insufficiency); b) “euvolaemic hyponatremia” observed in 
primary polydipsia, hypothyroidism and in SIADH, a 
disorder determined by an excessive hypothalamic or 
ectopic secretion of vasopressin, which can be caused by a 
large number of pathologies (pituitary adenoma, 
encephalitis, other CNS disorders; cancer such as lung 
cancer, pancreatic carcinoma, thymoma; pulmonary 
inflammatory states; drugs as DDAVP, oxytocin, 
carbamazepine, tryciclics, cyclophosphamide, tioridazine) 
; c) “hypervolaemic hyponatremia”, also called diluitional, 
observed in oedematous states that cause a fluid overload: 
acute or chronic congestive heart failure (CHF), liver 
cirrhosis, acute and chronic renal failure. (Table I). (6) 
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HYPONATREMIA: CONVENTIONAL THERAPY 
The conventional treatments of hyponatraemia differ 
according to the underlying disease. 
Hypovolaemic hyponatremia simply requires the 
administration of lost fluids in the form of isotonic saline. 
As far as euvolaemic and hypervolaemic hyponatremia are 
concerned, the use of hypertonic saline solution is 
reserved for severe hyponatremia with neurological 
symptoms. The correction of the sodium intake should be 
slow and gradual and not exceed 8-12 mEq/l in the first 24 
hours in case of acute hyponatremia, even slower in 
correcting chronic hyponatraemia (maximum 8 mEq/l in 
24 h). Overly rapid correction, in fact, can cause serious 
and irreversible neurological disorders, such as the 
pontine myelinolysis due to brain glial damage 
(oligodendrocytes) (7, 8, 9, 10, 11). Osmotic 
demyelination syndrome results in confusion, behavioral 
changes, dysphagia, dysarthria, mutism, spastic 
hemiplegia or quadriplegia, convulsions, coma, death (3). 
Other conventional treatments used in managing 
hyponatremia consist in water restriction and loop 
diuretics (oedematous states). Lithium and 
Demeclocycline, capable of correcting hyponatremia 
causing nephrogenic insipidus diabetes, are rarely used 
because of their side effects and only under certain 
conditions (SIADH). Mannitol and urea (12) can be used 
to induce osmotic diuresis with increased excretion of free 
water. 
Most of these therapies are of moderate efficacy. In any 
case it is important to monitor blood volume and assess 
frequently sodium levels (i.e. more a day by ABG), as 
well as other electrolytes, urine output, renal and 
cardiovascular function when correcting the serum 
sodium. None of the conventional therapies directly 
addresses the effects of elevated vasopressin levels, which 
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ARGININE VASOPRESSIN AND VAPTANS 
Arginine Vasopressin or ADH (Antidiuretic hormone) is a 
cyclic peptide (9 amino-acids) with a disulfide bridge. It is 
synthesized in the hypothalamus (sopraoptic and 
paraventricular nuclei) and transported along the axons to 
the posterior lobe of hypophysis. It is released into the 
circulation in response to a number of stimuli (13). These 
stimuli can be osmotic (osmoreceptors situated in the 
anterior hypothalamus) or non-osmotic (low-pressure 
baroreceptors, present in large veins, right and left atrium, 
lungs; high-pressure receptors, present in the carotid 
sinuses and aortic arch). Other non-osmotic stimuli are 
hypovolemia, stress, hypoglycemia, nausea and vomiting, 
drugs. Circulating ADH is metabolized by a 
vasopressinase (also called oxytocinase or placental 
leucine aminopeptidase), widely expressed on cellular 
membrane. Well known ADH receptors are: V1a, V1b 
(also known as V3), V2. They belong to G-protein-
coupled receptor superfamily. V1a and V1b receptors 
activate the phospholipase C/protein kinase C pathway, 
while V2 receptor activates the cAMP/protein kinase A 
pathway. 
V1a receptor (expressed on surface of vascular smooth 
muscle cells, cardiomyocytes, platelets, hepatocytes, brain 
and muscle uterine cells) regulates vasoconstriction, 
inotropic effect, platelets aggregation, glycogenolysis, 
anxiety and stress, myocyte hypertrophy (14). V1b 
receptor, found in anterior pituitary gland, increases 
release of ACTH (15). V2 receptor is expressed on 
endothelial cells, where it determines release of von 
Willebrand factor, and on the basolateral membrane of the 
principal cells of the renal collecting ducts, where 
determines a water reabsorbition through the synthesis and 
insertion in the luminal membrane of the water channel 
aquaporina-2 (AQP2) (16). 
According to antidiuretic action of V2 receptor, since the 
80’s a large number of vasopressin antagonists has been 
investigated to treat hyponatremia. Because of limits 
linked to their peptide structure, the first peptide 
vasopressin antagonists were abandoned in favor of non-
peptide vasopressin antagonists, also known as vaptans. 
Non-peptidic vasopressin antagonists (i.e. vaptans) are: 
mozavaptan (OPC 31260) (17), lixivaptan (VPA 985) 
(18), conivaptan (YM 087) (19), satavaptan (SR 121463) 
(20), tolvaptan (OPC 41061) (21). (TABLE II). 
Until now two vaptans have been released for clinic use: 
conivaptan, as an intravenous preparation, and tolvaptan, 
as an oral tablet. 
Conivaptan (Vaprisol®) was the first medication of this 
class to be approved by the FDA in 2005 for the treatment 
of hyponatremia in SIADH, hypothyroidism, pulmonary 
disorders and adrenal insufficiency in hospitalized patients 
(22) and two years later, in 2007, also for hypervolemic 
hyponatremia in hospitalized patients (23). The loading 
dose is 20 mg i.v. over 30 min and the maintenance dose 
is 20-40 mg i.v. for continuous infusion over 24h up to 
96h. Differently from all the other vaptans, which are 
selective V2-receptor antagonists, conivaptan acts like a 
V1a-receptor and V2-receptor antagonist. This singularity 
could be investigated in a randomized trial to show if 
conivaptan is better than other vaptans in treating 
hyponatremic patients with CHF thanks to its 
cardiovascular action (V1a-receptor blockage causes 
reduction of vascular peripheral resistance and inhibits 
unfavorable myocardial remodeling). It is metabolized by 
CYP3A4. Common side effects are infusion site reactions, 
fever, hypokalemia, hypotension, gastrointestinal 
disturbances. Udelson reported that a single iv dose of 
conivaptan increased urine output and reduced PCWP 
(pulmonary capillary wedge pressure) in patients with 
advanced heart failure (NYHA class III or IV) (46). 
Tolvaptan (Samsca®) was approved by FDA for treatment 
of euvolemic and hypervolemic hyponatremia in HF, 
cirrhosis and SIADH, and by EMEA for treatment of 
SIADH (24, 25) only. The initial dosage is 15 mg once 
daily, increasing to 30-60 mg/day depending on clinical 
response. Like conivaptan it is metabolized largely by 
CYP3A4, so there are some warnings about interactions. 
The main adverse reactions are weakness, dry mouth, 
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 Lixivaptan Tolvaptan Conivaptan Satavaptan 
V1a:V2 affinity  1:100 1:29 10:1 1:112 
Route of 
administration 
oral oral intravenous oral 
Dosage twice a day once a day continuous 
infusion 
once a day 
Na⁺  excretion/24 h ↔ (small dose) 
↑ (bigger dose) 
↔ ↔ ↔ 
Aquaresis effect + + + + 












We searched  CENTRAL (The Cochrane Central Register 
of Controlled Trials) and PubMed databases from January 
2000 to January 2012. We searched for “vasopressin 
receptor antagonists” AND “hyponatremia”. In PubMed 
we applied filter for “Randomized Clinical Trial” and 
“Controlled Clinical Trial”. No language restrictions were 
imposed. According to these criteria 17 trials are 






In table III (Results) these studies, sorted in chronological 
order, are described and commented in a systematic 
manner, according to a scheme that shows references; the 
typology of study; the vaptan used, the population 
enrolled and size of the two groups (drug versus placebo); 
the pharmacological intervention and the primary and 
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a) Gheorghiade M 






b) Hyponatremia in 
chronic HF. 
 
c) n=254 patients: 
 
- n=191 tolvaptan 
(n=64: 30 mg 
 n=64: 45 mg 
 n=63: 60 mg). 
 
- n=63 placebo. 
a) fixed doses of 30, 45, 60 
mg/die without fluidic 
restriction and with stable 
furosemide doses. 
 
b) 25 days. 
 
c) Primary efficacy 
variable: change in body 
weight at day 1 vs 
baseline. 
A decrease in 
body weight and 
an increase in 
urine output 
doses-related 
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b) Hyponatremia in 
liver cirrhosis and 
ascites . 
 
c) n=60 patients: 
 
- n=40 lixivaptan  
  (n=22: 100 mg  
   n=18. 200mg).         
 
- n=20 placebo. 
a) Primary end-point: 
s[Na⁺ ] ≥ 136 mmol/l. 
 
100mg/die per os vs 
200mg/die per os vs 
placebo 
           with 
water restriction (max 
1l/die). 
 
b) 7 days. 
 
c)  s[Na⁺ ] normalization in 
2 following measurements. 
Normalization in 
27% 100 mg/die 
group vs 50% in 
200 mg/die vs 0% 
in placebo, 
respectively 






associated with a 
slight decline 
(8%) of the GFR. 
 
 







b) Hyponatremia in 
liver cirrhosis, HF, 
SIADH. 
 
c) n=44 patients: 
 
- n=33 lixivaptan  
  (n=12: 25 mg                        
   n=11: 125 mg 
   n=10: 250 mg). 
 
- n=11 placebo. 
a) fixed doses of 25mg/bid 
vs 125 mg/bid vs 250 
mg/bid per os  vs placebo  
           with 
water restriction (max 1.5 
l/die) 





c) changes in s[Na⁺ ], body 












side effects that 
determined 
suspension of 
treatment in 5 
patients. 
a) Schrier RW ( Study of 
Ascending Levels of 
Tolvaptan in 
Hyponatremia (SALT 







b) Hyponatremia in 
liver cirrhosis, HF, 
SIADH. 
 
c) n=448 patients: 
 
- n=225 tolvaptan 
a) increasing doses of 
tolvaptan 15, 30, 60 
mg/die per os in 30 days. 
 
b) 37 days (30 days of 
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(p<0.001 for all 









Translational Medicine @ UniSa, - ISSN 2239-9747 2012, 3(1): 1-14 
 
6 
Università degli Studi di Salerno 
 
- n=223 placebo. 
 
c) -Mean outcome: daily 
s[Na⁺ ] 
 
     -Secondary Outcome: 
changes in body weight, 
total changes in s[Na⁺ ]. 
comparisons). 
 
-Dry mouth and 
thrist s(Na⁺ )≥146 








associated with a 
significant 
improvement of 
the mental health 
status measured 
by the SF-12 
Questionnaire. 
 
This was the first 
study showing 
the benefits of a 
long-term 
treatment  of 
hyponatremia 
with an oral 
vaptan.   
 
a) Gheorghiade M (Am J 








b) Hyponatremia in 
liver cirrhosis, HF, 
SIADH. 
 
c) n=28 patients: 
 
- n=17 tolvaptan. 
 
- n=11 placebo + 
water restriction. 
 
a) increasing doses of 
tolvaptan 15, 30, 45, 60 
mg/die per os in 14 days. 
Follow up in out-patient 
clinic. 
 
b) 65 days. 
 
c)  - Primary outcome: 
normalization of  or a  
s[Na⁺ ] ≥10% increase 
from baseline. 
 
     -Secondary outcome: 
changes in s[Na⁺ ], CH2O, 
plasma osmolarity and 
thrist. 
Tolvaptan appears 
to be more 
effective than 









a) Soupart A (Clin J Am 
Soc Nephrol 2006). (31) 
 
b) double-blind (1st 













 n=34 patients: 
 
- n=26 satavaptan              
  (n=14: 25 mg 
   n=12: 50 mg). 
 
 






 phase: fixed dose of 
satavaptan 25 or 50 mg/die 
per os . 
2
nd
 phase: increasing doses 
of 12.5, 25, 50 mg/die 
               with 





  phase: 7-30 days 
    2
nd
  phase: 12 months 
 
c) s[Na⁺ ] normalization in 
first 24h, body weight, AP. 
 
Significative 
increase in s(Na⁺ ) 
in patients 
assuming 
satavaptan 25 mg 
(p<0.01) and 50 




term treatment, 15 
of 18 enrolled 
patients achieved 
6 mo and 10 
achieved 12 mo of 
treatment. 
 





-However  10% 
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treatment and the 
s(Na⁺ )  response 
was maintained 





a) Ghali J (J Clin 







b) Hyponatremia in 
liver cirrhosis, HF, 
SIADH. 
 
c) n=74 patients: 
 
 - n=51conivaptan    
   (n=24: 40 mg 
    n=27: 80 mg).                                                    
 
 - n=23 placebo. 
a) fixed doses of 
conivaptan 40 and 80 
mg/die in two doses. Max 
water intake 2 l/die 
 
b) 5 days. 
 
c)  change from baseline in 
s[Na⁺ ] area under the 
curve. 
conivaptan shows 
a dose dependent 




















a) Konstam MA (The 
Efficacy of Vasopressin 
Antagonism in Heart 













chronic HF with 
signs of volume 
overload, ejection 
fraction ≤40%, 
NYHA class III or 
IV simptoms. 
 
c) n=4133 patients: 
 
- n=2072 tolvaptan. 
   
 
- n=2061 placebo. 
 
a) fixed doses tolvaptan 30 
mg/die or placebo in 
addition to standard 
therapy. 
 
b) at least 60 days 
 
c) Outcomes 
c.1) Dual Primary 
outcomes: 
   -1) all-cause mortality 
(superiority and 
noninferiority) 
   -2) cardiovascular death 
or hospitalization for heart 
failure (superiority only). 
 
c.2) Secondary outcomes: 
- changes in dyspnea, body 




During a median 
follow-up of 9.9 
months, 537 
patients (25.9%) 
in the tolvaptan 
group and 543 


















points of day 1 
patient-assessed 
dyspnea, day 1 
body weight, and 
day 7 edema. In 
In this trial 
tolvaptan was 






The study, with a 
large number of 
patients and a 
long-term follow-
up, shows that 
tolvaptan has no 
effect on long-
term mortality or 
heart failure-
related morbidity; 
but it also shows 
that tolvaptan is 
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and dry mouth, 
but frequencies of 
major adverse 
events were 











a) Zelster D (Am J 






b) Hyponatremia in 
liver cirrhosis, HF, 
SIADH. 
 
c) n=84 patients: 
 
- n=55 conivaptan              
  (n=29: 40 mg 
   n=26: 80 mg). 
 
- n=29 placebo. 
a) 20 mg i.v. bolus 
followed by a continuos 
96h i.v. infusion of 40 
mg/die and 80 mg/die with 
fluidic restriction (max 2 
l/die). 
 
b) 96 h 
 
c) Primary outcome: 
change in s[Na⁺ ], 
measured by the baseline-











area under the 
[Na+]-time curve 
during the 4-day 









(p < 0.001 vs. 
placebo, both 
doses). 
-This trial shows 
the rapid 
effectiveness of 






is not considered.  
a) Ginès P (HypoCAT; 






b) Hyponatremia in 
liver cirrhosis with 
ascites. 
 
c) n=110 patients: 
 
- n=82 satavaptan  
  (n=28: 5 mg/die 
   n=26: 12.5 mg/d 
  n=28: 25 mg/di) 
 
- n=28 placebo 
 
a) fixed doses of 
satavaptan 5, 12.5, 25 
mg/die of with fluidic 
restriction (max 1.5 l/die).  
All patients received 
spironolactone at 100 
mg/day. 
 
b) 14 days. 
 
c) Main Outcome: changes 
in body weight from 
baseline (day 1) to the end 
of treatment (day 14) and  
chenges in s[Na⁺ ] from 
baseline to day 5. 
Improved control 
of ascites, as 
indicated by a 
reduction in body 
weight (p = 0.05 




serum sodium (p< 










-The trial shows 
that  satavaptan 
improves the 
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placebo.  
 
The frequency of 
other adverse 
events was similar 
among groups. 
 
a) Annane D (Am J Med 






b) Hyponatremia in 
liver cirrhosis, HF, 
SIADH. 
 
c) n=83 patients: 
 
- n=53 conivaptan 
  (n=27: 40 mg 
   n=26: 80 mg). 
 
- n=30 placebo.  
a) fixed doses of oral 
conivaptan 40 and 80 
mg/die with oral fluidic 
restriction (max 2l/die). 
 
b) 5 days. 
 
c) Main outcome: baseline-
adjusted area under the 
s[Na⁺ ]-time curve. 
A normal s[Na⁺ ]  
or an increase 





conivaptan 40 and 
80 mg/die (67% 
and 88%, 
respectively) than 























c) n=151 patients: 
 
- n=115satavapta 
   (n=39: 5 mg 
    n=36: 12.5 mg 
    n=40: 25 mg). 
 
- n=36 placebo 
a) fixed doses of 
satavaptan 5, 12.5, 25 
mg/die or placebo and 
spironolactone 100 mg/die. 
 
b) 12 weeks. 
 
c) frequency of 
paracentesis 
The frequency of 
paracentesis was 
decreased 










and thirst were 
more common 
with satavaptan. 
The trial included 
patients with or 
without 
hyponatraemia, 
and normal to 
mildly abnormal 
renal function. 
a) Naidech AM 




randomized pilot (goal N 




patients with severe 
hyponatremia (< 
130 mE/l) or 
Hyponatremia 
(<135 mEq/l) with 
depressed GCS. 
 
c) n= 20 
a) Conivaptan bolus (20 
mg iv) followed by 20 mg 




c) changes in serum and 
urine electrolytes and 
clinical examinations. 
Conivaptan led to 
higher s[Na⁺ ]  
compared to usual 





was difficult: the 
study was 








a) Abraham WT (The 
BALANCE Study: 
Treatment of 
Hyponatremia Based on 
Lixivaptan in NYHA 
Class III/IV Cardiac 
Patient Evaluation; Clin 








c) n=652 patients: 
a) doses of lixivaptan or 
placebo adjusted on 
s[Na⁺ ]  or volume status. 
 
b) 60 days. 
 
c) Increase in s[Na⁺ ]   
from baseline. Body 
Lixivaptan led to 
higher s[Na⁺ ]  





to address unmet 
questions 
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(phase III trial). 
- n=326 lixivaptan 
- n=326 placebo 




a) Aronson D (Short- 
and long-term treatment 
of dilutional 
hyponatraemia with 
satavaptan: the DILIPO 









(<135 mEq/l) in 
CHF. 
 
c) n= 118   
a) Satavaptan 25 mg/die vs 
50 mg/die vs placebo. 
 
b) 4 days (double-blind 
treatment), followed by 
non-comparative open-
label satavaptan therapy 
for up to 343 days. 
 
c) s[Na⁺ ]≥ 135 mEq/l 
and/or an increase in ≥ 5 
mEq/l above baseline. 
Clinical measures. 
 













Higher rates of 
adverse events 













a) Galton C (Neurocrit 











c) n=10 patients: 
- n=5: conivaptan  
- n=5: only usual 
care 
a) a single dose 20 mg 
conivaptan. 
 
b) 48 h 
 
c) s[Na⁺ ], sodium load, 
change in ICP, urine 
output. 
At 4 h, serum 
sodium was 
higher (P = 0.02) 
and ICP was 
lower (P = 0.046) 
in the conivaptan 
group.  
 
24-h but not 48-h 
urine output was 
different between 
the two groups (P 















needed to assess 
the role of 




a) Koren MJ (Am J 










c) n=49 patients. 
a) Conivaptan 20 mg/die 
or 20 mg/bid or placebo 
via 30-minute i.v. infusion. 
 
b) 48 h. 
 
c) Change in s[Na⁺ ] from 





with those in the 
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the most common 





The analysis of the mentioned trials shows that non-
peptide vasopressin antagonists are safe and effective 
drugs in the short-term correction of hyponatremia in both 
the states of hypervolemia (liver cirrhosis and heart 
failure) and euvolemia (SIADH).  
Certainly vaptans have a number of limitations. First of 
all, trials presented a percentage of 10-20% of patients 
who do not respond to treatment. The reason for this 
phenomenon has not yet been studied well. This can be 
partly attributed to altered pharmacokinetics (altered 
volume of distribution in oedematous states and water 
ingestion), in part to polymorphisms and mutations in the 
vasopressin receptors (43, 44). On the other hand, vaptans 
may be associated with rapid correction of sodium values 
(> 12 h mEq/l/24) with potential risk of pontine 
myelinolysis, although the literature has not reported any 
cases of this complication in patients treated with these 
drugs.  
Clinical response to vaptans in terms of aquaresis and 
hyponatremia correction is not the same in all subsets of 
patients. Patients with SIADH are those that respond best, 
while those with liver cirrhosis worse. Probably in the 
state of hypervolemia (CHF, liver cirrhosis) proximal 
tubular reabsorption reduces the effect that vaptans cause 
in distal tubular ducts. Further studies are needed to 
clarify this point. So clinicians need to keep in mind that 
therapy with vaptans should be individualized for each 
patient. 
All studies were short term. Only Soupart (31) and 
Aronson (40) studied the effectiveness of satavaptan for 
one year, in SIADH and CHF respectively, demonstrating 
the efficacy and good tolerability in long-term treatment. 
There are no studies comparing the efficacy between 
vaptans and traditional treatment (diuretics, hypertonic 
saline, urea,…) or between two different vaptans. This last 
point is considerable because, whereas conivaptan and 
mozavaptan (used in Japan for the treatment of 
hyponatremia in paraneoplastic SIADH)also block the 
V1a receptors, they may have superior efficacy compared 
to satavaptan, tolvaptan and lixivaptan (which are 
selective V2-receptor antagonists) in patients with heart 
failure. 
 
All vaptans induce thirst and this effect is very important 
for compliance to therapy. Without doubt, the thirst is 
explained by the increased plasma osmolality that they 
determine, but it may be also linked to a direct action on 
vasopressin receptors of “thirst” in hypothalamic neurons. 
In recent years the use of vaptans for treatment of 
emergency hyponatremia (45) and for the control of serum 
sodium and intracranial hypertension in neurosurgical 
patients has been discussed (38, 41). For the correction of 
emergency hyponatremia, hypertonic saline remains the 
treatment of choice, but it has been hypothesized that 
vaptans could at least be taken into account to give a 
slower correction of sodium rate than hypertonic saline 
and no risk of pulmonary edema (45). With regard to the 
treatment of cerebral edema and intracranial hypertension 
in neurosurgical patients, the current target is to keep the 
patient “salty and full”, with careful monitoring and rapid 
intervention to keep within normal limits the plasma 
osmolality and serum sodium (as well as the optimization 
of respiratory and cardiovascular functions, in addition to 
sedation, to guaranty an adequate DO₂ /VO₂ ) through the 
consolidated use of mannitol, hypertonic saline, diuretics. 
To the best of our knowledge, there are still no conclusive 
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Vaptans are safe and effective drugs in the short-term 
treatment of hyponatremia due to hypervolaemic 
edematous states (liver cirrhosis, heart failure) and 
euvolaemic states (SIADH). They are contraindicated in 
hypovolaemic hyponatremia. About superiority of one 
vaptan above the other and comparison between vaptans 
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